KR20240004706A - 신경내분비 종양을 치료하기 위한 조성물 및 방법 - Google Patents

신경내분비 종양을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240004706A
KR20240004706A KR1020237041028A KR20237041028A KR20240004706A KR 20240004706 A KR20240004706 A KR 20240004706A KR 1020237041028 A KR1020237041028 A KR 1020237041028A KR 20237041028 A KR20237041028 A KR 20237041028A KR 20240004706 A KR20240004706 A KR 20240004706A
Authority
KR
South Korea
Prior art keywords
octreotide
patient
administration
composition
lipid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041028A
Other languages
English (en)
Korean (ko)
Inventor
프레드릭 티버그
Original Assignee
캐머러스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캐머러스 에이비 filed Critical 캐머러스 에이비
Publication of KR20240004706A publication Critical patent/KR20240004706A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237041028A 2021-05-04 2022-04-26 신경내분비 종양을 치료하기 위한 조성물 및 방법 Pending KR20240004706A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2130118-9 2021-05-04
SE2130118 2021-05-04
PCT/SE2022/050404 WO2022235186A1 (en) 2021-05-04 2022-04-26 Compositions and methods for treating neuroendocrine tumors

Publications (1)

Publication Number Publication Date
KR20240004706A true KR20240004706A (ko) 2024-01-11

Family

ID=83932120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041028A Pending KR20240004706A (ko) 2021-05-04 2022-04-26 신경내분비 종양을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20250281569A1 (https=)
EP (1) EP4333874A4 (https=)
JP (1) JP2024517204A (https=)
KR (1) KR20240004706A (https=)
CN (1) CN117241822A (https=)
AU (1) AU2022271139A1 (https=)
CA (1) CA3217408A1 (https=)
IL (1) IL308133A (https=)
MX (1) MX2023013060A (https=)
WO (1) WO2022235186A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731247A1 (en) * 2023-06-20 2026-04-29 Camurus AB Compositions and methods for treating acromegaly

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
GB201402423D0 (en) * 2014-02-12 2014-03-26 New Injection Systems Ltd Auto-injector assembly
MX383392B (es) * 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime

Also Published As

Publication number Publication date
MX2023013060A (es) 2023-11-15
EP4333874A1 (en) 2024-03-13
AU2022271139A1 (en) 2023-10-12
WO2022235186A1 (en) 2022-11-10
CN117241822A (zh) 2023-12-15
US20250281569A1 (en) 2025-09-11
IL308133A (en) 2023-12-01
JP2024517204A (ja) 2024-04-19
CA3217408A1 (en) 2022-11-10
EP4333874A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
Juif et al. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
US11980606B2 (en) Use of marizomib for the treatment of central nervous system (CNS) cancers
KR20090016707A (ko) Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
US20240091316A1 (en) Ghrh or analogues thereof for use in treatment of hepatic disease
KR20240004706A (ko) 신경내분비 종양을 치료하기 위한 조성물 및 방법
CN118715010A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
AU2010257328A1 (en) Method of treatment using GH antagonist and somatostatin agonist
US20250152674A1 (en) Oral octreotide for treatment of disease
EA053081B1 (ru) Композиции и способы лечения нейроэндокринных опухолей
US20170258815A1 (en) Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes
EP4731247A1 (en) Compositions and methods for treating acromegaly
JP2020517648A (ja) 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
AU2024337423A1 (en) Igf2 fusion protein formulations and therapeutic uses thereof
TW202517250A (zh) Ｌｐ（ａ）干擾劑化合物之治療用途及劑量
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations
CN117355323A (zh) 用于治疗骨关节炎的方法
CN117222671A (zh) Adamts结合免疫球蛋白的施用方法
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000